Cancer Immunotherapy Market Report 2026: Strategic Insights and Revenue Outlook

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer immunotherapy market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Cancer Immunotherapy Market show for the 2026–2030 period?

The cancer immunotherapy market has experienced substantial expansion in recent years. This market is projected to grow from $124.09 billion in 2025 to reach $137.99 billion by 2026, driven by a compound annual growth rate (CAGR) of 11.2%. Historically, this expansion can be linked to significant breakthroughs in tumor immunology, an increasing global incidence of cancer, the early triumphs of monoclonal antibodies, augmented funding for oncology research and development, and the regulatory approval of checkpoint inhibitors.

The cancer immunotherapy market is anticipated to experience substantial growth over the next few years, with projections indicating it will reach $210.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.1%. This expected expansion can be attributed to several factors, including the increasing adoption of CAR T-cell therapies, the broadening scope into solid tumor indications, higher investments in cancer vaccines, a growing demand for targeted combination therapies, and supportive reimbursement policies for immunotherapy. Furthermore, key trends in the forecast period involve the rapid embrace of immune checkpoint inhibitors, a rising utilization of combination immunotherapy regimens, the ongoing expansion of cell-based cancer treatments, a heightened focus on personalized immunotherapy, and an increasing number of oncology clinical trials.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp

What Drivers Are Shaping The Development Of The Cancer Immunotherapy Market?

The anticipated increase in cancer incidence is projected to propel the cancer immunotherapy market. Factors such as tobacco use, alcohol consumption, obesity, a sedentary lifestyle, and environmental influences are contributing to the global rise in cancer cases. This growth in cancer diagnoses is expected to heighten the demand for cancer immunotherapies, as patients are increasingly seeking medical treatments that offer better recovery and less pain. For instance, in July 2024, according to projections published by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are forecasted to increase for most types between 2023-2025 and 2038-2040, with rises ranging from less than 1% for breast cancer to 50% for eye cancer. Conversely, a smaller number of cancers are expected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Therefore, the escalating cancer incidence is anticipated to boost demand for cancer immunotherapy during the forecast period.

Which Segments Are Contributing To The Growth Of The Cancer Immunotherapy Market?

The cancer immunotherapy market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy

2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma

3) By End User: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists

4) By Vaccines: Therapeutic Cancer Vaccines

5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

Which Trends Are Influencing The Performance And Direction Of The Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are prioritizing the development of novel solutions, including PD-1 immunotherapies, to broaden access to advanced immune-based treatment options for individuals with hard-to-treat cancers. A PD-1 immunotherapy is a treatment specifically targeting immune checkpoints, engineered to stimulate antitumor immune activity by impeding programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company focused on oncology and biologics, launched HETRONIFLY (Serplulimab). This therapy is recognized as the first programmed death-1 inhibitor globally approved for extensive-stage small cell lung cancer, utilizing a dual mechanism that targets PD-L1 and PD-L2 with robust receptor internalization to enhance immune engagement. Its demonstrated survival benefit and considerably reduced cost compared to existing immunotherapies highlight its clinical worth and improve patient access to advanced cancer treatment in India.

Who Are The Primary Competitors In The Global Cancer Immunotherapy Market?

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Cancer Immunotherapy Market?

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Immunotherapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6768&type=smp

Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795